🇺🇸 PROUDLY AMERICAN COMPANY — U.S. owned & operated · Ships from the USA 🇺🇸
For research purposes only · Not for human consumption · You must be 21+ to purchase
Cart
Home / News / Retatrutide vs Tirzepatide vs Semaglutide
Comparison Published August 2, 2026

Retatrutide vs Tirzepatide vs Semaglutide: One, Two, or Three Receptors

These three compounds are constantly discussed together, and the reason is structural: they represent a stepwise ladder of receptor engagement. Semaglutide hits one incretin receptor. Tirzepatide hits two. Retatrutide, still investigational, hits three. Understanding what each added receptor contributes is the clearest way into this literature — and the 2026 Phase 3 data lets us look at whether adding receptors keeps paying off at the same rate.

The three receptors

Side by side

Compound Receptors Reported peak weight reduction Status
SemaglutideGLP-1~15–17%Approved
TirzepatideGLP-1 + GIP~20–22%Approved
RetatrutideGLP-1 + GIP + glucagon~24–29% (up to 28.3% at 12 mg in TRIUMPH-1)Investigational

The TRIUMPH Phase 3 program

Retatrutide's pivotal trials run under the TRIUMPH name. The reported readouts:

The manufacturer has indicated plans to submit for U.S. approval in Q1 2027. Until a regulatory decision, retatrutide remains investigational.

The part worth noticing: diminishing returns

Run the gaps. Semaglutide to tirzepatide — adding the GIP receptor — is roughly a 7–8 percentage point step. Tirzepatide to retatrutide — adding the glucagon receptor — is roughly 6 points. The third receptor adds real effect, but it adds less than the second one did.

That is a meaningful observation for anyone reading this literature. The "more receptors is proportionally better" intuition does not hold cleanly, and it raises the obvious research question about where the curve flattens. It also explains why the next wave of compounds under study — amycretin, pemvidutide, mazdutide, VK2735 — are not simply stacking more receptors, but exploring different combinations and different pharmacokinetics.

Why this comparison dominates search

Roughly 60% of peptide-related search volume in the U.S. concerns weight loss, and the top three peptide search terms are all GLP-1 receptor agonists, together accounting for over 2.2 million monthly searches. Retatrutide's own search interest grew over 500% year over year — the second-fastest growth of any peptide term in 2026. Interest here dramatically outpaces regulatory status.

Research use only. This article summarizes published clinical trial results and mechanistic literature. It is not medical advice and makes no safety, efficacy, or treatment claim for humans or animals. Retatrutide is an investigational compound and is not approved for any use. All products sold by Universe Peptide are supplied strictly for laboratory research only, not for human or animal consumption, 21+. No dosing or administration guidance is provided.

Retatrutide for laboratory research

Universe Peptide supplies Retatrutide for in-vitro laboratory research, with a third-party Certificate of Analysis (COA) available for each lot:

Browse GLP research compounds →

Related reading

Sources & further reading